Related by context. All words. (Click for frequent words.) 75 ECCMID 73 ICAAC IDSA 73 AACR NCI EORTC 73 AASLD 73 ASCO Annual Meeting 72 ASH Annual Meeting 72 CROI 71 SABCS 71 #th Annual Interscience 71 Antimicrobial Agents 70 Gastrointestinal Cancers Symposium 69 ECTRIMS 69 AACR #st Annual Meeting 68 Digestive Disease Week DDW 68 #th Interscience Conference 67 Genitourinary Cancers Symposium 67 st Annual Meeting 67 Late Breaker 67 Interscience Conference 67 EORTC NCI AACR 67 ADA Scientific Sessions 67 nd Annual Meeting 67 Hematology Annual Meeting 66 Clinical Oncology Annual Meeting 66 Hematology ASH Annual Meeting 66 EORTC NCI AACR Symposium 66 EASL 66 Chemotherapy ICAAC 66 Retroviruses 66 Opportunistic Infections CROI 66 ASCO GI 66 AASLD Meeting 66 Digestive Disease Week 65 Prostate Cancer Symposium 65 AACR San Antonio 65 CTRC AACR San Antonio 65 Transcatheter Cardiovascular Therapeutics TCT 65 ACR ARHP 65 ARVO 64 Annual Scientific Sessions 64 AACR 64 radezolid 64 Breast Cancer Symposium 64 Hematology Meeting 64 Hematology ASH 64 Endocrine Society Annual Meeting 64 AACR Annual Meeting 64 #nd EORTC NCI 64 UEGW 63 AACR Meeting 63 Molecular Targets 63 Breast Cancer Symposium SABCS 63 ISPOR 63 ASGT 63 Therapeutics TCT 63 Clinical Oncology ASCO Annual 63 ASCO GU 62 AACR #nd Annual Meeting 62 Keystone Symposia 62 Society CTOS 62 AHA Scientific Sessions 62 Digestive Diseases Week 62 Rheumatology ACR Annual 62 International Myeloma Workshop 61 Carfilzomib 61 th Interscience Conference 61 ASCO Genitourinary Cancers Symposium 61 ASCO 61 Cambridge Healthtech Institute 61 ESMO 61 Annual ICAAC 61 Connective Tissue Oncology 61 ASBMR 61 Alzheimer Disease ICAD 61 delafloxacin 61 Scientific Sessions 61 Pediatric Academic Societies PAS 61 Opportunistic Infections 61 Thiovir 61 PROSTVAC TM 60 Clinical Trial Results 60 AUA Annual Meeting 60 ASCO Breast Cancer 60 Oral Presentations 60 Molecular Medicine Tri 60 BIO InvestorForum 60 GTCbio 60 Biological Therapy 60 ACR ARHP Annual 60 ECCO ESMO 60 Medical Oncology ESMO 60 Therapeutics TCT scientific 60 EuroPCR 60 Clinical Microbiology 60 Endocrine Society ENDO 60 EORTC NCI 60 #st Annual Meeting 60 AABB Annual Meeting 59 Symposium SABCS 59 Antiviral Activity 59 San Antonio Breast Cancer 59 League Against Rheumatism 59 Liver Meeting 59 AAPS Annual Meeting 59 Clinical Dermatology 59 Poster Session 59 oral FTY# 59 Preclinical Data 59 Clinical Virology Symposium 59 HCV SPRINT 59 Canaccord Adams Hepatitis C 59 DDW 59 Immunogenicity 59 BIOCOM Investor Conference 59 Telbivudine 59 EULAR 58 AAN Annual Meeting 58 ECNP 58 Rheumatology Annual 58 AACR EORTC NCI 58 Vitro Activity 58 Cethromycin 58 Poster Presentation 58 Phase Ib study 58 AIDS Vaccine 58 Oligonucleotide Therapeutics Society 58 DDW ® 58 ORAL Sync 58 HQK 58 ERA EDTA 58 BAL# [001] 58 Phase Ib II 58 Pediatric Academic Societies 58 AACR Frontiers 58 Preclinical Study 58 Immunology Annual Meeting 58 ganetespib 58 Annual Transcatheter Cardiovascular 58 annual Transcatheter Cardiovascular 58 ASM Biodefense 58 Poster Presentations 58 Endocrine Society #st 58 Blinatumomab 58 ASTRO Annual Meeting 58 Influenza Vaccines 58 targeting CD# 58 Traficet EN 57 Phase 1b trial 57 Gastroenterology ACG Annual 57 Gastrointestinal Cancer 57 Radezolid 57 RGB # 57 ENDO 57 entitled Synergistic 57 EASD 57 Clinical Oncology ASCO 57 HCV Protease Inhibitor 57 Cancer iSBTc 57 Nephrology Renal Week 57 Phase 2b Clinical Trial 57 Valortim R 57 Scientific Session 57 CCX# 57 Telaprevir 57 Scientific Meeting 57 Neurology Annual Meeting 57 Transcatheter Cardiovascular Therapeutics 57 Abstract Number 57 HuMax CD4 57 Cancers Symposium 57 preclinical efficacy 57 ZFP Therapeutic 57 HUPO 57 Chicago Multidisciplinary Symposium 57 Oral Presentation 57 CRLX# 57 NEUGENE 57 Fifth Decennial International 57 Respiratory Society 57 iclaprim 57 BAL# [002] 56 Liver EASL 56 Therapeutics Roundtable 56 International Papillomavirus 56 AACR symposium 56 & Immunology AAAAI 56 nanoviricides 56 pharmacokinetic PK 56 viral kinetic 56 vivo efficacy 56 Vascular Biology ATVB 56 IASLC 56 #nd Annual Meeting 56 HuMax EGFr 56 SAEM Annual Meeting 56 ASMS Conference 56 Phase Ib clinical 56 randomized discontinuation trial 56 Endocrine Society #nd 56 Valopicitabine 56 Heart Failure Society 56 SCCHN 56 Infectious Diseases ECCMID 56 Phase 2a trial 56 American Thoracic Society 56 VEITHsymposium 56 Targeted Anticancer Therapies 56 PCK# 56 SNM Annual Meeting 56 EORTC 56 LymphoStat B 56 ongoing Phase 1b 56 solithromycin 56 Oritavancin 56 SPIRIT IV 56 Breaking Clinical Trials 56 TG MV 56 Vaccine Adjuvant 56 EUROGIN 56 iPrEx 56 Poster Discussion 56 Potent Antiviral Activity 56 Arteriosclerosis Thrombosis 55 R roscovitine 55 PRTX 55 II Clinical Trial 55 teriflunomide 55 Hsp# Inhibitor 55 Phase #/#a 55 non nucleoside inhibitor 55 ABRF 55 Cardiovascular Therapeutics 55 Abstract # 55 Oncology ASTRO 55 European CanCer Organisation ECCO 55 Glufosfamide 55 HIF PHI 55 Talabostat 55 CALGB 55 Phase III ALLEGRO 55 Reverset 55 Annual Meeting 55 Malignant Lymphoma 55 Inflammatory Arthritis 55 ASCO abstract 55 Pharmaceutical Scientists AAPS 55 AACC Annual Meeting 55 Phase 2a 55 Related Viruses 55 PEG SN# 55 AACR NCI EORTC Molecular 55 Experimental Biology EB 55 Oral Fingolimod 55 BIO VentureForum East 55 Therapeutic Radiology 55 Dendritic Cells 55 Stent Thrombosis 55 CAMMS# 55 Annual Interscience Conference 55 Respiratory Viral Infections 55 Liver Diseases AASLD 55 oral prodrug 55 Randomized Phase 55 entecavir 55 NO# [002] 55 Biodefense Vaccines 55 Cancer Immunotherapy 55 Antiviral Therapy 55 EULAR Annual 55 C# BioVentures 55 PSN# [002] 55 Gastroenterology ACG 55 HFSA Annual 55 CLL8 55 BioProcess International 55 DermaVir Patch 55 INGN 55 Cachexia 54 Guanilib 54 HCV Genotype 54 Autoimmunity 54 INCB# [001] 54 Solid Tumors 54 Antiviral Research 54 viral kinetics 54 EFNS 54 USpella 54 DIA Annual Meeting 54 DAS# [001] 54 proteasome inhibitor 54 PXD# 54 ON #.Na 54 Prostate AdenoCarcinoma Treatment 54 fosbretabulin 54 Hematology 54 NSTI Nanotech 54 AIR2 Trial 54 AGBT 54 Zenvia Phase III 54 CLEO QELS 54 Antiviral 54 tolerability profiles 54 histone deacetylase HDAC inhibitor 54 th Annual Interscience 54 Cardiostim 54 #rd Annual CTRC 54 Tanespimycin 54 Double Blind Placebo 54 ASHG 54 HDAC Inhibitor 54 pan HDAC inhibitor 54 Aflibercept 54 LD Micro 54 pharmacokinetic PK study 54 ® DDW 54 CYT# 54 phase 2a 54 ISTH 54 Therapeutic Targets 54 vascular disrupting agent 54 Microbiology ASM 54 www.asco.org 54 ASTMH 54 MERLIN TIMI 54 AAAS Annual Meeting 54 Neuropathic Pain 54 ISHLT 54 BiTE R 54 Drug Formulation 54 antiviral compounds 54 Sym# 54 phase IIb 54 Phase III psoriasis 54 PEGylated interferon beta 1a 54 Neurology AAN 54 Antibody Therapeutics 54 MT#/MEDI-# 54 FOLOTYN ® 54 huC# DM4 54 cyclophilin inhibitors 54 Malignant Mesothelioma 54 BioPharm America 54 abstracts summarizing 54 Phase 1b 54 MT# MEDI 53 EOquin TM 53 Aplidin R 53 Tesetaxel 53 recurrent glioma 53 Belimumab 53 Reports Preclinical Data 53 Bortezomib 53 depsipeptide 53 ENMD # 53 GASTRO 53 Clinical Trial Data 53 transthyretin TTR mediated amyloidosis 53 phase Ib 53 Deforolimus 53 ASCO Gastrointestinal Cancers Symposium 53 BioContact Quebec 53 Retrovirus 53 Preclinical Studies 53 Phase 2a Study 53 enzastaurin 53 Cancer Vaccines 53 Tarvacin TM 53 HORIZONS AMI 53 BRIM3 53 EGEN 53 XmAb# 53 Cancer Therapeutic 53 Opexa 53 Advanced Neuroendocrine Tumors 53 PROactive Study 53 OHR/AVR# 53 Gynecologic Cancer Society 53 panobinostat 53 AAO HNSF Annual Meeting 53 SAWC WHS 53 Monoclonal Antibodies 53 CCR5 antagonist 53 NEUGENE R 53 Universal Flu Vaccine 53 Boceprevir 53 Metastatic Melanoma 53 Related Disorders ICAD 53 multicenter trials 53 compound AEZS 53 xenograft models 53 AAAAI Annual Meeting 53 Denufosol 53 HDAC Inhibitors 53 CEQ# 53 Pharmacoeconomics 53 CAPRISA 53 ImmunoVEX HSV2 53 Hematology ASH Meeting 53 Cancer Therapeutics 53 Therapeutic Radiation 53 LibiGel ® 53 Hana Biosciences 53 Human Genetics ASHG 53 Hypertension ASH 53 AP# [003] 53 Phase #/#a trial 53 Gene Therapy ASGT 53 Sipuleucel T 53 Phase 2b trial 53 TLR antagonists 53 SUCCEED trial 53 COPIC Energy 53 AVADO 53 Selective Cardiac Myosin 53 Targeted Therapies 53 OXi# 53 huN# DM1 53 ENDEAVOR III 53 Combination REOLYSIN R 53 NEUVENGE 53 Bazedoxifene 53 Elvitegravir 53 AAPM 53 Presents Preclinical Data 53 Antisense 53 PreCISe 53 Diabetes EASD 53 Dalbavancin 53 oral Xeloda 53 Long Awaited Reality 53 preclinically 53 Pooled Analysis 53 HCV NS5B polymerase 53 Aplidin 53 Association EHA 53 Atrial Fibrillation Symposium 53 Altastaph 53 Pharmacokinetics 52 Phase 2a clinical 52 AACR Symposium 52 Inhalation Solution 52 Brentuximab Vedotin SGN 52 AEZS 52 GRN#L 52 Multimeric 52 PROSTASCINT R 52 refractory chronic myeloid 52 Clinical Efficacy 52 Neoplasia 52 CTRC AACR 52 Hepatocellular Carcinoma 52 selective kinase inhibitor 52 Azedra 52 TASKi2 52 ZD# [001] 52 Dr. Pingpank 52 Pharmacoepidemiology 52 ASGCT 52 Immunotherapeutic 52 http:/www.genmab.com 52 LD MICRO Conference 52 Antimicrobial Chemotherapy 52 RTOG 52 Biotech Showcase 52 ACC.# 52 neratinib 52 YONDELIS 52 Idenix Pharmaceuticals 52 BiTE antibody MT# 52 ENDEAVOR IV 52 EpCAM 52 mitogen activated ERK kinase 52 perifosine 52 Archexin 52 VEITHsymposium ™ 52 REACH Registry 52 alvespimycin 52 Immunologists 52 AACR IASLC Joint 52 Plicera 52 Phase IIA 52 AEG# 52 forodesine 52 HuMax CD# 52 SU# [003] 52 Phase 2a Trial 52 Cystic Fibrosis Conference NACFC 52 Clinical Oncology Gastrointestinal Cancers 52 evaluating mipomersen 52 talabostat 52 KRN# 52 DAS# Fludase ® 52 Systemic Delivery 52 DermaVir 52 vidofludimus 52 Ambrisentan 52 AA Amyloidosis 52 Podium Presentation 52 OneMedForum 52 Advanced Renal Cell 52 torezolid phosphate 52 non nucleoside HCV 52 ESTRO 52 LT NS# 52 Sangamo BioSciences Announces 52 PKC# 52 Diabetic Macular Edema 52 GTCbio 3rd 52 Cardiovascular Disease Epidemiology 52 HyQ 52 Adefovir 52 CALGB # [002] 52 Therapeutic Vaccine 52 www.aacr.org 52 Romidepsin 52 Phase III Trials 52 IMGN# 52 Ampligen ® 52 phase IIa 52 Kahalalide F 52 BCIRG 52 Cell Biology ASCB 52 iSBTc 52 ENESTnd 52 PITTCON 52 Controlled Release 52 BRIM2 52 Annual BIO 52 Omacetaxine 52 HCV polymerase inhibitors 52 Phase Ib 52 Hedgehog antagonist 52 ISSWSH 52 Venereology EADV 52 Targretin 52 Cloretazine R 52 NASDAQ CXSP announced 52 Kinase Inhibitor 52 elotuzumab 52 ASN Renal Week 52 Mineral Research ASBMR 52 JAK Inhibitor 52 Protease Inhibitors 52 PROSTVAC VF 52 Factor VIIa 52 Enzastaurin 52 EACTS 52 prostate cancer mCRPC 52 liposome injection 52 Acute Heart Failure 52 phase IIb study 52 evaluating tivozanib 52 Anti Tumor 52 NanoViricides 52 Protease Inhibitor 52 epigenetic therapies 52 Windhover Therapeutic Area 52 Tarvacin 52 Protein Therapeutics 52 OMP #M# 52 Dr. Yatscoff 52 Clinical Oncology 52 Elagolix 52 CYT# potent vascular disrupting 51 CCR5 mAb 51 ACUITY trial 51 Presents Positive 51 SAWC 51 VRX# [001] 51 CR# vcMMAE 51 BOLDER II 51 Interferon Gamma 51 CUDC 51 Interventional Radiology SIR 51 rALLy trial 51 Vascular Annual Meeting 51 Cytotoxicity 51 Abstracts 51 Innate Immunity 51 daptomycin 51 Solorel TM 51 Tumor Biology 51 Virulizin ® 51 pharmacodynamic properties 51 Valortim 51 Hedgehog Pathway Inhibitor 51 Phase Ib Clinical Trial 51 Hematological Malignancies 51 Aggressive Reduction 51 Viral Hepatitis 51 Nordic ACTI 51 APOPTONE 51 Lysosomal Disease Network 51 REG2 51 CTAP# Capsules 51 pertuzumab 51 SPIE Photonics West 51 EVEREST II 51 velafermin 51 ToGA 51 Androgen Receptor 51 MEND CABG 51 Presents Preclinical 51 BIO# 51 SAR# [004] 51 phase IIb trial 51 acute PAO 51 vascular disrupting agents 51 riociguat 51 Perifosine 51 & OTO EXPO 51 EndoTAG TM -1 51 trastuzumab DM1 T DM1 51 LBH# 51 Pirfenidone 51 Preclinical 51 phase IIa clinical 51 MERIT ES 51 HCV protease 51 PANVAC VF 51 randomized Phase III 51 Mass Spectrometry ASMS 51 BIBW 51 ROCKET AF 51 clevidipine 51 AAAAI 51 ponatinib 51 MVA BN R 51 HCV RESPOND 2 51 TMC# C# 51 MEK inhibitors 51 Cardiology Scientific Sessions 51 ALN TTR 51 Pediatric Academic Society 51 perifosine KRX 51 Biophysical Society 51 ExTRACT TIMI 51 axitinib 51 NASDAQ SLXP today 51 Safinamide 51 brivaracetam 51 Inflammatory Bowel Diseases 51 DU #b 51 Tarvacin Anti Viral 51 PROVENGE sipuleucel T 51 USA# strain 51 PestWorld 51 EAACI 51 TAXUS ATLAS 51 JNJ Q2 51 OneMedPlace Finance Forum 51 Genta Incorporated OTCBB GETA 51 Phase 2a Clinical Trial 51 Hedgehog pathway inhibitor 51 Nasdaq IDRA today 51 C# BioVentures Conference 51 Symadex 51 Retrovirus Conference 51 multicenter Phase 51 Angiolix 51 Phase IIB 51 Oral Abstract 51 JAK1 51 Wound Healing Society 51 DASISION 51 standard chemotherapy regimen 51 Dose Escalation 51 novel histone deacetylase 51 fidaxomicin Phase 3 51 Liver Disease AASLD 51 BiOS 51 LUX Lung 51 Protexia R 51 LigoCyte 51 Placebo Controlled Trial 51 Phacilitate Vaccine Forum 51 Cloretazine ® 51 AAG geldanamycin analog 51 attenuated strain 51 dose escalation clinical 51 BioContact Québec 51 RNAi Therapeutic 51 Urology EAU 51 Breaking Clinical Trial 51 AVERROES 51 preclinical pharmacokinetic 51 America HFSA 51 Inc. Nasdaq AVRX 50 Quinamed 50 nucleotide analog 50 Liposomal 50 YONDELIS R 50 Polymerase Inhibitor 50 ABCSG 50 RECORD1 50 Gleevec imatinib mesylate 50 Dr. Siegall 50 Respiratory Virus 50 entinostat 50 RNAi Therapeutics 50 HBeAg + 50 Developmental Therapeutics Immunotherapy 50 ELACYT 50 romidepsin 50 Well Tolerated 50 XL# SAR# 50 CAMPATH 50 EXPAREL ™ 50 vitro cytotoxicity 50 OncoVEX GM CSF 50 sorafenib tablets 50 Plenary Session 50 Tesmilifene 50 HIF PH inhibitors 50 GVAX ® 50 Clinical Chemistry AACC 50 Aganocide 50 Radiation Oncology ASTRO 50 Nasal Powder 50 TIDES Oligonucleotide 50 Amrubicin 50 HspE7 50 Microbicide 50 A3 adenosine receptor 50 Phase 2b study 50 GLP toxicology studies 50 Cardiovascular Renal Physiology 50 MASCC 50 Safety Tolerability 50 Lenocta 50 www.pranabio.com 50 bazedoxifene conjugated estrogens 50 farletuzumab 50 voreloxin 50 BioCentury Future Leaders 50 Dasatinib 50 oral JAK1 50 See CLINICAL PHARMACOLOGY 50 Vaxfectin R formulated 50 oral proteasome inhibitor 50 evaluating REVLIMID 50 quinolone resistant 50 Squalamine 50 obatoclax 50 assessing T DM1 50 Glucosamine Chondroitin Arthritis 50 TLR7 50 NRTI resistance 50 BiTE ® 50 Pivotal Clinical Trial 50 Systemic Sclerosis 50 REGiMMUNE 50 RE LY trial 50 VAX# 50 Actilon 50 Vector Borne 50 BRAF inhibitor 50 seliciclib 50 ProLindac 50 Autoimmune Diseases 50 CHEST 50 BioAlliance Pharma 50 EADV 50 influenza VLP vaccine 50 Cancer Therapies 50 Xanafide 50 ZYBRESTAT 50 p# inhibitor 50 ZFP Therapeutic TM 50 ImQuest 50 Tolamba 50 polymerase inhibitors 50 SA FC# 50 Valortim TM 50 Hyphanox 50 Clinical Oncologists 50 ThermoDox ® clinical 50 Zarnestra 50 ASCRS 50 TXPO 50 BioNumerik 50 Hormone Refractory Prostate Cancer 50 sulodexide 50 Rheumatology Annual Meeting 50 Fulvestrant 50 Tigecycline 50 zanolimumab 50 DiLA2 50 Recurrent Chest Wall 50 HER2 positive metastatic breast 50 Chronic Lymphocytic Leukemia 50 JAK2 Inhibitor 50 HIMSS# Interoperability Showcase 50 Oncogene 50 Ophthalmology ARVO 50 HPTN 50 CA4P 50 Present Preclinical Data 50 Retroviral 50 clinical pharmacology studies 50 Clinical Gastroenterology 50 ACAAI 50 Neck Surgery Foundation 50 J Clin Oncol 50 TLR9 agonist 50 ritonavir boosted 50 ExL Pharma 50 resolvin 50 Daclizumab 50 Environ Health Perspect 50 Rigel R# 50 MDV# 50 MLN# 50 ESCRS 50 Hygiene ASTMH 50 Vertex telaprevir 50 eyeforpharma 50 Alinia 50 telcagepant 50 Phase III AFFIRM 50 Chronix 50 placebo controlled clinical 50 ICAD 50 NASDAQ CYTK announced 50 TRO# 50 Interventions SCAI 50 Pharmacodynamics 50 trabectedin 50 antitumoral 50 Valortim ® 50 Ocular Diseases 50 nucleoside analog 50 BARI 2D 50 CRMD# 50 Molecular Diagnostics 50 GW# [003] 50 Nephrology ASN Renal 50 VIRxSYS 50 TCAD therapy 50 Cardiotoxicity 50 multicenter Phase II 50 Castration Resistant Prostate Cancer 50 INTERPHEX# 50 metastatic castration resistant 50 Successfully Completes Phase 50 Announces Poster Presentations 50 Tetraphase 50 CUSTOM II 50 Molecular Therapy 50 Edge STudy 50 NOVAVAX 50 liposomal formulation 50 angiogenesis inhibitor 50 atacicept 50 dose escalation trial 50 Anticancer Drugs 50 DAVANAT 50 Randomized Phase II 50 galiximab 50 Apoptone 50 amrubicin 50 pediatric acute lymphoblastic 50 tkRNAi 50 Prolongs Survival 50 Natalizumab 50 Novel Therapeutics 50 Endovascular Therapy ISET 49 verteporfin 49 preclinical 49 NITD# 49 Sphingomab 49 ORMD 49 ularitide 49 darinaparsin ZIO 49 orally inhaled migraine 49 Phase 2b 49 administered subcutaneously 49 www.novelos.com 49 CIRSE 49 Entry Inhibitor 49 LabAutomation 49 HDL Selective Delipidation 49 Xcytrin R 49 Biologic Therapy 49 Personalized Immunotherapy 49 Novel Inhibitor 49 INSPIRE Trial Phase III 49 Antiangiogenic 49 Ocular Pharmacology 49 HORIZONS AMI trial 49 Delcath Phase III 49 adenoviral vectors 49 HGS# 49 Hagop M. 49 AAEP Convention 49 rALLy 49 ASCO Prostate Cancer 49 Extensively Drug Resistant Tuberculosis 49 Antibody Engineering 49 Lung Transplantation 49 Hematological 49 Pazopanib 49 Emerging Infectious Diseases 49 Monoclonal Antibody 49 INCB# [002] 49 PERSEUS 49 sapacitabine 49 Printable slides 49 peptide antigens 49 PNP inhibitor 49 Capsule Endoscopy 49 CIBMTR 49 phosphatidylserine PS targeting 49 Epilepsy Society 49 SMT C# 49 Panzem 49 programs visit http:/www.bionovo.com 49 antitumor activity 49 tanespimycin 49 Demonstrates Efficacy 49 Unither 49 BioVant 49 Varespladib 49 Recombinant Human 49 Pivotal Trial 49 NAREIT REITWeek 49 ISMB 49 Teriflunomide 49 Ocrelizumab 49 Arch Surg 49 trodusquemine 49 Interferon Beta 49 PSMA ADC 49 Urocortin 2 49 Initiated Phase 49 CBLC# 49 VLP vaccine 49 alemtuzumab Campath 49 vivo preclinical 49 NEUGENE antisense 49 CoFactor 49 ISTODAX ® 49 Velcade bortezomib 49 maximally tolerated dose 49 Cempra 49 eltrombopag 49 Preclinical Evaluation 49 Drugs Affecting Lipid 49 Acquired Immune Deficiency Syndromes 49 indibulin 49 TLR antagonist 49 GlassBuild America 49 EmTech @ MIT 49 Neuro Oncology SNO 49 Fondation Ipsen 49 SMi 49 Ovarian PLCO Cancer 49 HDL Mimetic Peptide 49 Uplinq 49 Oligonucleotides 49 tasocitinib 49 Thermo Scientific booth 49 Genital Infection 49 sipuleucel T 49 isavuconazole 49 Actemra 49 GRNCM1 49 InterGrowth 49 Clinical Antipsychotic Trials 49 Vaccine Immunology 49 JMP Securities Healthcare 49 Immunology ACAAI 49 Breast Surgeons 49 Diabetic Macular Edema DME 49 Inc. Nasdaq OPTR 49 EFORT Congress 49 HIV integrase inhibitor 49 relapsed refractory multiple myeloma 49 Meets Primary Endpoint 49 Therapeutic Advances 49 CSCMP Annual Conference 49 Bevirimat 49 Immunosuppression 49 ECNP Congress 49 TH PO# 49 ADVANCE PD 49 metaglidasen 49 NABTT 49 Defibrotide 49 anticancer compound 49 metastatic hormone refractory 49 Pharmacodynamic 49 Homspera 49 CYT# novel 49 Diabetic Neuropathy 49 decitabine 49 Cardiology ESC Congress 49 Phase 2b RESTORE CLI 49 Angiogenesis